•
Sep 30, 2024
CervoMed Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
CervoMed reported a net loss of $4.8 million for the third quarter of 2024, compared to a net income of $2.2 million for the same period in 2023. As of September 30, 2024, CervoMed had approximately $46.7 million in cash, cash equivalents and marketable securities.
Completed final patient visits in RewindD-LB Phase 2b trial evaluating neflamapimod in patients with early-stage DLB and began preparing for database lock.
Topline data from the RewindD-LB study is expected in December 2024.
Preparing for Phase 3 trial initiation in mid-2025 after planned end-of-Phase 2 meeting with the FDA.
Plan to initiate a Phase 2a trial to evaluate neflamapimod’s potential to promote recovery from ischemic stroke in the first quarter of 2025.